» Articles » PMID: 35998675

Off-the-shelf Cryopreserved Platelets for the Detection of HIT and VITT Antibodies

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2022 Aug 23
PMID 35998675
Authors
Affiliations
Soon will be listed here.
Abstract

Heparin-induced thrombocytopenia (HIT) is suspected much more often than it is confirmed. Technically simple platelet factor 4 (PF4)-polyanion enzyme-linked immunosorbent assays (ELISAs) are sensitive but nonspecific. In contrast, accurate functional tests such as the serotonin release assay, heparin-induced platelet activation assay, and PF4-dependent P-selectin expression assay require fresh platelets and have complex assay end points, limiting their availability to specialized reference laboratories. To enable broad deployment of functional testing, we sought to extend platelet viability significantly by optimizing storage conditions and developed a simple functional assay end point by measuring the release of a platelet α-granule protein, thrombospondin-1 (TSP1), in an ELISA format. Platelet cryopreservation conditions were optimized by freezing platelets at controlled cooling rates that preserve activatability. Several-month-old cryopreserved platelets were treated with PF4 or heparin and were evaluated for their ability to be activated by HIT and vaccine-induced immune thrombotic thrombocytopenia (VITT) antibodies in the TSP1 release assay (TRA). HIT and spontaneous HIT patient samples induced significantly higher TSP1 release using both PF4-treated (PF4-TRA) and heparin-treated cryopreserved platelets relative to samples from patients suspected of HIT who lacked platelet-activating antibodies. This latter group included several patients that tested strongly positive in PF4-polyanion ELISA but were not platelet-activating. Four VITT patient samples tested in the TRA activated PF4-treated, but not heparin-treated, cryopreserved platelets, consistent with recent data suggesting the requirement for PF4-treated platelets for VITT antibody detection. These findings have the potential to transform the testing paradigm in HIT and VITT, making decentralized, technically simple functional testing available for rapid and accurate in-hospital diagnosis.

Citing Articles

Diagnostic Complexity in Monoclonal Gammopathy of Thrombotic Significance.

Kanack A, Leung N, Padmanabhan A N Engl J Med. 2024; 391(20):1961-1963.

PMID: 39565997 PMC: 11581683. DOI: 10.1056/NEJMc2409428.


Critical Analysis of Thrombocytopenia Associated With Glycoprotein IIb/IIIa Inhibitors and Potential Role of Zalunfiban, a Novel Small Molecule Glycoprotein Inhibitor, in Understanding the Mechanism(s).

Rikken S, van t Hof A, Ten Berg J, Kereiakes D, Coller B J Am Heart Assoc. 2023; 12(24):e031855.

PMID: 38063187 PMC: 10863773. DOI: 10.1161/JAHA.123.031855.


Vaccine-induced immune thrombotic thrombocytopenia: what do we know hitherto?.

Roytenberg R, Garcia-Sastre A, Li W Front Med (Lausanne). 2023; 10:1155727.

PMID: 37261122 PMC: 10227460. DOI: 10.3389/fmed.2023.1155727.


Vaccine-induced immune thrombotic thrombocytopenia (VITT) after SARS-CoV-2 vaccination: Two cases from Germany with unusual presentation.

Edmonds R, Schonborn L, Habben S, Paparoupa M, Greinacher A, Schuppert F Clin Case Rep. 2023; 11(1):e6883.

PMID: 36698527 PMC: 9859986. DOI: 10.1002/ccr3.6883.


Vaccine-induced immune thrombotic thrombocytopenia.

Kanack A, Padmanabhan A Best Pract Res Clin Haematol. 2022; 35(3):101381.

PMID: 36494147 PMC: 9467921. DOI: 10.1016/j.beha.2022.101381.

References
1.
Hicks L, Bering H, Carson K, Haynes A, Kleinerman J, Kukreti V . Five hematologic tests and treatments to question. Blood. 2014; 124(24):3524-8. DOI: 10.1182/blood-2014-09-599399. View

2.
Padmanabhan A, Jones C, Curtis B, Bougie D, Sullivan M, Peswani N . A Novel PF4-Dependent Platelet Activation Assay Identifies Patients Likely to Have Heparin-Induced Thrombocytopenia/Thrombosis. Chest. 2016; 150(3):506-15. PMC: 5028397. DOI: 10.1016/j.chest.2016.02.641. View

3.
Warkentin T, Hayward C, Smith C, Kelly P, Kelton J . Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med. 1992; 120(3):371-9. View

4.
Buda V, Andor M, Cristescu C, Tomescu M, Muntean D, Baibata D . Thrombospondin-1 Serum Levels In Hypertensive Patients With Endothelial Dysfunction After One Year Of Treatment With Perindopril. Drug Des Devel Ther. 2019; 13:3515-3526. PMC: 6791256. DOI: 10.2147/DDDT.S218428. View

5.
Vayne C, Rollin J, Gruel Y, Pouplard C, Galinat H, Huet O . PF4 Immunoassays in Vaccine-Induced Thrombotic Thrombocytopenia. N Engl J Med. 2021; 385(4):376-378. PMC: 8174029. DOI: 10.1056/NEJMc2106383. View